Podcasts about healthtech

It's our monthly Digital Health Download, and September's stories all circle the same tension: technology keeps promising to fix healthcare's problems, but just as often it moves them somewhere else, or creates new ones entirely. This week, Halle unpacks a news-heavy month, weighing who actually benefits as markets, algorithms, and AI get closer to our health decisions.We cover:Americans can now bet on clinical trials and FDA regulatory reviews - but do we want that?Meta's massive settlement over harming childrenThe surprising reason AI might be making healthcare more expensive instead of lessA new study on the biggest lever we're not pulling to bend the healthcare cost curveTwo lawsuits rattling a popular wearable and a celebrity-backed mental health startupWhat a widely used drug class reveals about bias in hiring, and the uncomfortable questions that raises⸺

We don't talk enough about how hard it actually is to build a healthcare startup. Behind SmarterDx's story, now one of the biggest health AI exits to date, were 18 months without a single customer, a pivot that seemed to make no product sense, and two co-founders who went back to working as hospitalists just to get by.In this episode, Steve gets the real story from Dr. Michael Gao and Dr. Joshua Geleris about the challenges they faced and what ultimately unlocked real growth and led to their billion+ acquisition by New Mountain Capital.We cover:Why their first product idea failed and what customer objections actually taught them to build insteadThe counterintuitive workflow that made contingency pricing possibleHow AI translation of clinical notes into billing codes now outperforms the average human, and what that means for coders and nursesWhy "moat" is the wrong metaphor and what a flywheel looks like insteadWhat they'd do differently in the acquisition processAbout our guests:Michael Gao, MD, the CEO and co-founder of SmarterDx. Prior to founding SmarterDx, Dr. Gao was the Medical Director for Transformation at NewYork-Presbyterian, where he led applied AI development, implementation, and strategy for the health system. Dr. Gao holds faculty positions at the Icahn School of Medicine at Mount Sinai and Weill Cornell Medicine. Dr. Gao completed his internship and residency in Internal Medicine at NewYork-Presbyterian.. He received his M.D. from the University of Michigan and a B.S from the University of California Los Angeles.Josh Geleris, MD, is the Head of Product and co-founder of SmarterDx. Prior to SmarterDx, he was Assistant Professor of Medicine at Columbia University, where he was funded by the National Institutes of Health and the Department of Defense for clinical informatics and data science, and led implementation of Epic for providers. Dr. Geleris completed his MD at the Technion-Israeli Institute of Technology and his Internal Medicine internship and residency at NewYork-Presbyterian. ⸺

This week on Pulse: Amplify, Louise and George speak with EMR pioneer Dr NT Cheung.Dr NT Cheung joined the Hong Kong Hospital Authority when clinical computing was virtually non-existent, and went on to help build one of the world's largest integrated, longitudinal electronic patient record systems.NT reflects on Hong Kong's remarkable 30-year digital health journey, why building its technology in-house proved so valuable, and what other health systems can learn from its clinician-led, incremental approach. They explore the extraordinary opportunity created by three decades of consistently collected patient data, cross-border record sharing with mainland China, and technology's role in supporting an ageing society.NT also offers a timely warning for the AI era: healthcare is too complex to be transformed by technology alone. AI may be extraordinarily powerful, but it remains a tool, and the goal must be to make every interaction between patients, clinicians and the health system a little smoother and better.Connect with NT on LinkedInVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

It's back-to-school szn, and while some kids are stressing over earlier wake-ups, this year's incoming medical students have a bigger question to answer: how do you train for a career that could still have you practicing medicine in the 2070s, when the tools of medicine are changing so rapidly?For our back-to-school episode, we sat down with Stanford University School of Medicine Dean Dr. Lloyd Minor to talk about how AI is already reshaping what future doctors learn and how they're taught, as well as what's still not working in American healthcare.We cover:What medical students are actually being taught about AI, and where Stanford still draws the lineWhy Stanford's tumor boards no longer start with humansThe surprising way Dr. Minor thinks AI could level the playing field in healthcare accessWhy the same AI tools helping patients feel more informed are also making them more anxiousThe counterintuitive reason new medical technology gets more expensive before it gets cheaperWhat's still standing in the way of a vision for precision medicine that's been decades in the makingAbout our guest:Lloyd B. Minor, MD, is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University. Dr. Minor also is a professor of Otolaryngology–Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University.As dean, Dr. Minor has had an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Medicine Children's Health. With his leadership, Stanford Medicine leads the biomedical revolution in Precision Health. His book, “Discovering Precision Health,” describes this shift to more preventive, personalized health care and highlights how biomedical advances are dramatically improving our ability to treat and cure complex diseases. In 2021, Dr. Minor articulated and began realizing a bold vision to transform the future of life sciences at Stanford University and beyond – a multi-decade journey enabled by Precision Health.In August 2023, Dr. Minor was appointed Vice President for Medical Affairs to lead all matters related to health and medicine at Stanford University.Before Stanford, Dr. Minor was provost and senior vice president for academic affairs of Johns Hopkins University. Prior to this appointment in 2009, Dr. Minor served as the Andelot Professor and director (chair) of the Department of Otolaryngology–Head and Neck Surgery in the Johns Hopkins University School of Medicine and otolaryngologist-in-chief of The Johns Hopkins Hospital.With more than 160 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders perhaps best known for discovering superior canal dehiscence syndrome, a debilitating disorder characterized by sound- or pressure-induced dizziness. He subsequently developed a surgical procedure that corrects the problem and alleviates symptoms.In 2012, Dr. Minor was elected to the National Academy of Medicine.—

Dans cet épisode de Cheminements, Marguerite de Rodellec reçoit Laurence Comte-Arassus, ancienne présidente de Medtronic France et GE HealthCare France, présidente du SNITEM et chevalière de la Légion d'honneur. Ensemble, elles abordent un sujet encore trop souvent fragmenté : la conciliation entre une très haute carrière de dirigeante dans la HealthTech et la maternité. Un échange puissant qui déconstruit les injonctions, prône l'écoute de soi et rappelle que diriger tout comme transmettre relèvent d'une même vocation : prendre soin des autres.Au programme de cet épisode :La naissance d'une vocation dans le dispositif médical : du désir de soigner sur le terrain au pilotage de grands groupes.L'expérience d'être la première femme à la tête de Medtronic France et les défis du leadership féminin.La maternité en parallèle d'une carrière intense : briser la peur de ne pas être une "bonne mère" et s'organiser sans culpabilité.La gestion des épreuves personnelles, de la maladie d'un enfant aux urgences professionnelles.Le mentorat et la sororité : la responsabilité d'aider les femmes à rester elles-mêmes sans chercher à copier les hommes.L'importance fondamentale de prendre soin de soi pour pouvoir durablement prendre soin des autres.Dans Cheminements, des femmes du quotidien, vos voisines, vos collègues, vos sœurs, partagent leurs parcours de santé mentale, physique ou sociale, entre luttes, victoires et transformations, pour mettre en lumière des sujets trop souvent passés sous silence.

Jessica and Jessica from SomX chatted through all the best news from this week with help from Barlett Data's Tom Bartlett.00:00 – Intro & setup06:38 – Why Tom spoke out35:15 – A coordinated campaign?50:49 – Where FDP falls short

Send us Fan MailWelcome back, everyone! In this episode, I'm diving deep into a topic that has been on every writer's mind lately: Artificial Intelligence. As a nurse with over 20 years of experience and a decade in the freelance health writing world, I've seen first-hand how AI is shifting the landscape. While it's certainly disrupted the industry, I want to share why I believe this is actually an incredible time for clinicians to pivot into writing.Key TakeawaysThe “Bottom” of the Market is Gone (and that's okay): AI has effectively taken over the low-paying, generic, high-volume “content treadmill.” While this has disrupted the market, it's not a loss for us. That type of work prioritized quantity over quality, and its decline opens up more space for meaningful, expert-driven content.Human Clinicians are Indispensable: AI lacks the ability to grasp the “gray areas” of medicine. It cannot replicate the clinical nuance, deep empathy, or the ability to interpret complex patient needs that a healthcare professional provides. Our expertise ensures clinical accuracy and a human tone that AI simply can't match.Growing Opportunities: Demand is actually increasing for clinicians in several key areas:Patient Education: Refining AI drafts to ensure they are empathetic and easy for patients to understand.Health Tech & Startups: Bridging the gap between technical engineering and medical accuracy.Ghostwriting: Helping healthcare leaders maintain their professional voice and authority.Continuing Education: Creating specialized professional development materials for other nurses.Actionable Steps1. Pick a Niche Based on Internalized Expertise: Identify a clinical area you know so well you could talk about it in your sleep. This “internalized” knowledge is your competitive advantage over AI.2. Define Your Positioning: Create a clear statement for your LinkedIn and pitches using this formula: “I help [target audience] with [specific service] so they can [desired result].”Thank you for tuning in! Remember, your clinical voice is more valuable now than ever. Keep writing, stay savvy, and I'll catch you in the next episode.Welcome to the Savvy Scribe Podcast, I'm so glad you're here! Before we start the show, if you're interested, we have a free Facebook group called "Savvy Nurse Writer Community"I appreciate you following me and listening today. I would LOVE for you to subscribe: ITUNESAnd if you love it, can I ask for a

Sharon Wood, founder and CEO of Happy People Games and creator of The New Forevers, a memory wellness company helping older adults, families, and caregivers reconnect through music, photos, and meaningful play.Through her two apps, Timeless Tunes and Still Frames, Sharon uses reminiscence therapy to stimulate memory, lift mood, and strengthen intergenerational connection for adults over 50, including those experiencing Alzheimer's, dementia, or mild cognitive impairment.Now, Sharon's journey from nearly four decades in gaming, including launching one of the most successful games, Grand Theft Auto, to building a new category in memory wellness shows how technology can be used for something deeply human.And while growing awareness for a space many families only discover once they are directly affected, she is helping people feel more connected, supported, and seen through the power of play.Here's where to find more:https://thenewforevers.com/ https://www.facebook.com/thenewforevers https://www.instagram.com/thenewforevers________________________________________________Welcome to The Unforget Yourself Show where we use the power of woo and the proof of science to help you identify your blind spots, and get over your own bullshit so that you can do the fucking thing you ACTUALLY want to do!We're Mark and Katie, the founders of Unforget Yourself and the creators of the Unforget Yourself System and on this podcast, we're here to share REAL conversations about what goes on inside the heart and minds of those brave and crazy enough to start their own business. From the accidental entrepreneur to the laser-focused CEO, we find out how they got to where they are today, not by hearing the go-to story of their success, but talking about how we all have our own BS to deal with and it's through facing ourselves that we find a way to do the fucking thing.Along the way, we hope to show you that YOU are the most important asset in your business (and your life - duh!). Being a business owner is tough! With vulnerability and humor, we get to the real story behind their success and show you that you're not alone._____________________Find all our links to all the things like the socials, how to work with us and how to apply to be on the podcast here:https://linktr.ee/unforgetyourself

This week on Pulse: Hot Topics, Louise and George explore the rapidly shifting boundaries of science, AI and human health.They unpack the extraordinary research using AI to design entirely new, functioning viruses, and the biosecurity questions that follow. Then, turning the discussion to South Australia's newly announced Royal Commission into AI and whether governance can possibly keep pace with technological change.Then they look at the emerging era of the “continuous human”: Germany's €40 million push to crack continuous hormone monitoring, and Google's enormous SensorFM foundation model, trained on more than a trillion minutes of wearable data, which could point towards a future of personalised, continuous health intelligence.Plus, George recommends Paper Guide for scientific research, and we highlight two international opportunities for clinicians to contribute to research on AI in healthcare.Research Opportunities:Clinicians – be part of the research into clinician use of AI, open globally LinkAI policy vs frontline reality survey (deadline 2 September) LinkResources:SPRIND Continuous Hormone Monitoring Challenge LinkIda Tin Coined Femtech. Now She's Funding Continuous Hormone Monitoring, Forbes LinkSensorFM: Towards a general intelligence and interface for wearable health data, Google Research LinkRecommendations:Paper Guide LinkVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Brendan McAdams, a seasoned healthcare sales coach and expert, to break down what it really takes to succeed in healthcare tech and medical sales. Brendan shares practical advice for both new and experienced reps, including how to stop selling too early, listen more effectively, ask better questions, build trust with customers, and approach sales conversations as a consultant rather than simply trying to make a sale. They also discuss how clinicians can transition into healthcare tech sales, the importance of preparation and organization, strategies for accessing hard-to-reach accounts, and how sales professionals can develop the right mindset to stay motivated and continuously improve. If you want actionable strategies to become a more confident, effective, and customer-focused medical sales professional, this episode is a must-listen. Connect with Brendan McAdams: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

Episode 82 - Matthew Whitty, former NHS England Director of Innovation, Research and Life Sciences and now Director of Commercial Partnerships at MDClone, discusses NHS data strategy, safe AI adoption and protecting patient privacy.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

מה באמת קורה כשסטארטאפ נלהב פוגש את הבירוקרטיה והמורכבות של מערכת הבריאות? בפרק סיכום העונה השנייה של 'עושים חדשנות בבריאות', סיון ורדי מארחת את אורי גורן, מנהל מרכז החדשנות במרכז הרפואי מאיר מקבוצת כללית, לשיחה פתוחה על מה שבאמת עובד ובעיקר על מה שמכשיל מיזמים מבטיחים עוד לפני שהם יוצאים לדרך.אורי חושף את הדגלים האדומים שגורמים לסטארטאפים ליפול כבר בפגישה הראשונה, ומסביר למה הפיתוח הקלאסי של "עוד מסך לרופא" הוא טעות קריטית שמפספסת לחלוטין את העומס הקליני בשטח. בהמשך השניים דנים באתגרים המורכבים של פתרונות B2C המבוססים על אימוץ מטופלים, ובשאלה החשובה: איך AI יכול לשנות את המשחק ולעזור לנו להפוך ל"חולים טובים יותר" שמנהלים את הבריאות של עצמם בצורה חכמה. פרק חובה לכל יזם ויזמת בתחום ה-HealthTech שמחפשים תובנות פרקטיות וטיפים מעשיים שיחסכו לכם זמן יקר, כסף וטעויות קריטיות בדרך להצלחה בסקייל.

We're on summer break and replaying one of our favorite episodes. This episode originally aired on September 22, 2025.A wearable can collect endless data, but it only matters if people trust it enough to change their behavior.In this replay, Oura CEO Tom Hale joins Steve and Michael to explain how the company combines clinical-grade accuracy with a consumer-friendly product. They discuss why the ring's form factor makes overnight tracking so powerful, how Oura turns physiological signals into useful guidance, and why the company is being pulled faster than expected into traditional healthcare.We cover:Why sleep data can reveal changes in the body before symptoms appearHow Oura designed a health product that supports users without judging or nagging themWhy accuracy is the foundation for trust, predictions, and behavior changeHow Oura navigates the boundary between wellness products and regulated medical devicesThe company's expansion into Medicare Advantage, women's health, metabolic health, and clinical care—About our guest:Tom Hale is the Chief Executive Officer at ŌURA and a member of its board. As the CEO he sets the company's business strategy and vision to make health a daily practice for members all over the world. He has over 30 years of experience across the technology and consumer product industry.Before joining ŌURA, Hale was president of Momentive where he drove B2B strategy and led product growth. During his time there he was instrumental in taking the company public in 2018, leading the team in key acquisitions, and driving the evolution and rebranding of the company into a multiple SAAS business. Previously, he held leadership roles at HomeAway and Linden Lab as the Chief Operating Officer and Chief Product Officer, respectively, and held executive roles at Macromedia and Adobe.Hale has a Bachelor of Arts from Harvard University and sits on the boards of Cars.com, RocketReach, and NoiseAware.—If you're enjoying the show, we would so appreciate it if you left us a review!—

The Art of Making a Room Feel Human with Mike Mosquito and Maureen Nylin Have you ever wondered why the smaller, more intimate industry events on your calendar seem to generate more real business than the massive trade show floors? On this episode, part two of their series The Intimacy Shift, host Adam Turinas sits down with Mike Mosquito and Maureen Nylin, the duo behind the Buzz podcast, to find out exactly what happens once buyers are in the room. If you are planning your 2027 event strategy and trying to figure out where your budget should actually go, this conversation gives you the answer. Mike and Maureen have built their careers on being the people event organizers call when they want a room to feel less like a trade show and more like a reunion, and they pull back the curtain on how they do it. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Join Michelle Wiltse, Founder and CEO of CompanAIn, for a grounded discussion on why the tech industry's rush toward "AI-first" branding often undermines true enterprise value. In a market flooded with companies rushing to wrap basic wrapper interfaces around large language models, Michelle took a radically different path. Having previously led agentic AI capabilities and deployed multi-agent systems for major global institutions, she chose to apply this frontier technology where it matters most: eliminating health data fragmentation for companion animals nationwide. In this episode, Michelle shares why the smartest AI strategy prioritizes deliberate restraint—using AI only where it solves genuine structural problems—and how a mission-driven mindset beats superficial "AI theater" every time.

This week on Pulse: Amplify, healthcare's digital future won't be built by technology - it will be built by people.In this episode, Louise and George are joined by Jane Dwelly, Vice President International at CHIME and Chair of the Federation for Informatics Professionals (FedIP), to discuss why professional recognition, leadership and workforce capability are critical to healthcare's future, especially as healthcare enters the AI era.They explore the UK's landmark move to recognise digital health professionals, what other countries can learn, how AI is reshaping workforce skills, and whether the future could include internationally recognised standards for digital health professionals.Connect with Jane on LinkedInResources:FedIP, Federation for Informatics Professionals LinkCHIME CXO Summit, September @Cambridge LinkCHIME membership LinkProfessional Membership for the NHS Digital, Data and Technology Workforce – NHS LinkVisitPulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

This month is about the gap between what a system offers and what people actually get from it: drugs that work better with support nobody's paying for, AI that's already answering more medical questions than most doctors ever will, and a labor market where staying healthy can mean staying stuck. Halle and Michael break down the stories reshaping digital health in August.We cover:Why GLP-1 funding is shifting from prescribing platforms into "companion" ecosystemsThe FDA panel vote that opens a legal pathway for six unapproved peptides, and what this could meanOur thoughts on OpenAI's new ChatGPT Health product, now available to every US adultThe Florida pastor's lawsuit against OpenAIWhy nearly one in four US workers are staying in jobs they'd rather leave, just to keep their health insuranceThe healthcare argument buried inside the bill to make daylight saving time permanentLinks:Rock Health, H1 2026 digital health funding recapHalle's research piece, Virtual GLP-1 startups: Pill mills or the future of obesity care?RAPS, FDA advisory committee backs six peptides for compounding listTechCrunch, OpenAI makes ChatGPT Health available to all US usersCBS News, ChatGPT's medical advice nearly killed a Florida man, lawsuit claimsGallup, One in four US employees locked in jobs for health insuranceThe Hill, House passes Sunshine Protection Act—

In this episode of Medsider Radio, we sat down with David Veino, President and CEO of Neuros Medical.Neuros is commercializing the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain.Before Neuros, David held senior commercial leadership roles at Cardiovascular Systems (CSI) and Stryker, and helped grow CSI's coronary and peripheral business from approximately $50 million to more than $250 million in annual revenue while leading key amputation-prevention initiatives. He also serves as a private equity advisor with Sectoral Asset Management. In this interview, David discusses how commercialization begins by mapping the patient journey upstream, what it takes to generate gold-standard clinical evidence for a novel therapy, how investors assess scalable medtech businesses, and how to build an investor pitch that earns the next meeting.  Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with David Veino, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:02) - David's 30-year medtech journey from cardiovascular devices to leading Neuros (04:38) - How Neuros is treating chronic post-amputation pain with on-demand neuromodulation (11:08) - Why Neuros completely changed its strategy halfway through the pivotal trial (15:36) - Why commercialization starts with referral pathways, not end-users (18:09) - How prosthetists became one of Neuros' most important referral sources (26:11) - What it takes to generate gold-standard clinical evidence for a first-of-its-kind therapy (37:41) - Building an investor pitch that earns the next meeting (41:42) - What gets David excited enough to invest in a medtech company

Curated Not Crowded – How to Win with Community-driven Events If you're a B2B healthcare marketer wondering whether your trade show budget is actually buying you anything real, this episode is for you. Host Adam Turinas sit down with Megan Antonelli, Founder and CEO of HealthIMPACT, to kick off a two-part series he's calling The Intimacy Shift, a look at why healthcare technology marketers are pulling money out of massive trade shows and putting it into smaller, curated, community-driven events instead. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

This week on Pulse: Hot Topics, Louise and George explore one question that underpins the future of digital health: how do we build trust?They begin with Australia's latest healthcare cyberattack and New Zealand's response to one of theirs, asking if cybersecurity should be considered a patient safety issue rather than simply an IT problem. The discussion then turns to the World Health Organization's first AI Readiness Assessment for Europe and what it reveals about the gap between rapid AI adoption and the governance needed to support it safely.The conversation moves to healthcare investment, examining Rock Health's latest funding report, new evidence on the economics of AI, and whether venture capital is backing the innovations that will deliver the greatest value for patients. Louise and George also discuss how patients are already using AI, drawing on new research from Microsoft and the Commonwealth Fund that reveals where people trust AI, and where they still want human care.Finally, they explore one of the first major lawsuits involving ChatGPT and alleged medical harm, asking how accountability will evolve as consumers increasingly rely on generative AI for health advice.Recommendations:Clinicians – be part of the research into clinician use of AI, open globally LinkAthens Digital Health Week, 23–25 February 2027, Royal Olympic Hotel, Athens LinkResources:Action Plan aims to strengthen Health NZ digital security, Pulse+IT (Reesh Lyon) — LinkHealth NZ Action Plan - LinkPartnered Health cyber incident statement — LinkWHO Europe statement: Govern AI in health before the gaps become irreversible — LinkWHO report: AI is reshaping health systems — state of readiness across the European Union — LinkRock Health H1 2026 Funding and Market Overview — LinkA systematic review of economic evidence of artificial intelligence in healthcare, Health Policy (Schmidt, Carter, McGuire, Mossialos, van Kessel) — Link2025 Global Women's Health Investment Hit A Record, But U.S. Investors Curb Their Enthusiasm, Forbes (Geri Stengel) — LinkGlobal analysis of country-level factors associated with chatbot usage for health, Nature Health — LinkPatients' Perspectives on AI in Primary Care, Commonwealth Fund — LinkChatGPT Led to a Man's Near-Fatal Health Crisis, Lawsuit Claims, The New York Times — LinkWith Thanks to Datacom:Download the Executive Briefing Playbook LinkVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters 

Episode 81 - Paul Gallagher is an award-winning health journalist with 20+ years' experience covering major UK health stories. A former Health Correspondent at The i Paper, he's a regular commentator on LBC, Times Radio and the BBC.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

Join Dr. Kal Patel, CEO and Co-Founder of BrightInsight, for an illuminating masterclass on navigating product-market fit (PMF) inside one of the most complex, highly regulated sectors in global business: healthcare. Every year, life science giants invest billions of dollars developing breakthrough biopharmaceutical therapies, yet nearly 50% of patients with chronic diseases drop off their prescribed medication regimes within the first twelve months. Drawing from his rare vantage point as a physician, former BCG strategist, former head of Amgen's Digital Health unit, and leader of BrightInsight, Dr. Patel breaks down why traditional "direct-to-consumer" wellness apps repeatedly fail, how to build enterprise software that biopharma giants trust to touch regulated therapies.

Every day, roughly 100 Americans die in crashes caused by human drivers. Yet when a self-driving car hesitates at an intersection or makes the news for an unusual mistake, public trust can evaporate.In this special episode, Dr. Jonathan Slotkin reads his latest Noema essay exploring why we demand perfection from machines while accepting human error as inevitable. Drawing on lessons from medicine, psychology, and autonomous vehicles, he argues that the biggest barrier to safer technology is trust.You'll learn:Why humans judge machine mistakes differently than human mistakesWhat healthcare learned about the difference between being safe and feeling safeWhy autonomous vehicles may already be far safer than human driversHow public perception can slow the adoption of life-saving technologyWhat every AI company should learn about transparency and trust —About our guest:Dr. Jonathan Slotkin is Chief Medical Officer for Strategy & Growth at Geisinger, where he drives growth at the intersection of care delivery, insurance, and digital transformation. A practicing neurosurgeon, he previously served as Geisinger's associate chief medical informatics officer.Jon's current research and writing examine safety, trust, and adoption of autonomous systems in public life. His New York Times guest essay on self-driving car safety was entered into the Congressional Record. His writing regularly appears in Harvard Business Review, STAT, and Noema Magazine. He has authored more than 70 peer-reviewed scientific publications.Previously, as co-founder and chief medical officer of Contigo Health, he partnered with the nation's largest employers to reimagine care for their associates. He co-founded Scrub Capital, a clinician-powered venture capital firm, where he serves as a Partner. He completed neurosurgery residency at The Brigham and Women's Hospital, Harvard Medical School, where he served as chief resident.—This piece was commissioned, edited, and published by Noema Magazine. Noema publishes longform journalism exploring fresh ideas. To read this piece and others, head to noemamag.com.—

In this episode of Medsider Radio, we sat down with Vijit Sabnis, co-founder and CEO of Adaptyx Biosciences.Adaptyx is a Stanford spinout developing wearable technology for continuous molecular monitoring.Over the past 20 years, Vijit has worked at the intersection of deep technology as an inventor, founder, and investor. Before Adaptyx, he was a Partner at Khosla Ventures and co-founded Solar Junction to commercialize high-efficiency solar cell technology. He holds a Ph.D. in Electrical Engineering from Stanford.In this interview, Vijit discusses how to recognize when a scientific idea is worth building a company around, how to build startup-style learning cycles when spinning technology out of academia, and designing products that are easy for clinicians and consumers to adopt. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Vijit Sabnis, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:17) - Vijit's path from Stanford, solar energy, and venture capital to building Adaptyx (07:25) - How Adaptyx is trying to do for hormones what continuous glucose monitors did for diabetes (13:50) - The signals Vijit looked for before founding Adaptyx (25:35) - How Adaptyx turned academic research into startup-speed learning cycles (32:15) - Why cortisol became the company's first clinical application (36:26) - How Adaptyx is designing new molecular data to fit existing clinical workflows (42:12) - Why new consumer health platforms opened new paths to commercialization (47:24) - Fundraising in an era of shorter attention spans

In the second of this two-part episode of French Insider, host Karl Buhler continues his conversation with Nicolas Nemeth, founder and CEO of Bonne et Filou, the French-inspired luxury "lifestyle" brand for dogs, and co-founder of Dumbo Health, a health tech startup focused on sleep apnea diagnosis and treatment. They discuss the mission behind Dumbo Health, the outdated state of sleep apnea diagnosis and treatment in the U.S., how the company is using AI to optimize a process that traditionally takes months into a matter of minutes, and what it means to build an "AI-native" company today.   What we discuss in this episode:   The mission behind Dumbo Health and the scale of the sleep apnea problem in the U.S. Why the current sleep apnea patient journey is slow, fragmented and difficult to navigate How Dumbo Health is digitizing diagnosis and treatment, from telehealth to at-home testing and device delivery Using AI and patient data to proactively coach patients and improve treatment adherence What it means to build an "AI-native" company versus simply integrating AI into existing workflows The shift from traditional software development to AI-driven, agent-based building processes How AI is reshaping investor priorities The cybersecurity risks that come with building fast in an AI-driven world The challenges of fundraising as a healthcare company in a market fixated on AI-agentic valuations   About Karl Buhler As an associate with the Corporate and Securities practice group and French Desk in Sheppard's New York office, Karl Buhler focuses on domestic and cross-border transactions, including mergers, acquisitions, joint ventures and complex commercial agreements in industries such as technology, communications, life sciences, energy, defense and aerospace. In particular, he advises foreign companies with the installation and development of their operations in the United States.   About Nicolas Nemeth Nicolas Nemeth is the co-founder of Dumbo Health, a digital sleep clinic that allows patients to skip the sleep lab and bring the entire obstructive sleep apnea journey home, and the Founder & CEO of Bonne et Filou, the first French-inspired luxury "lifestyle" brand for pets in the United States focused on delivering high-quality, luxury and innovative products in the pet industry. Nico began his career as an investment banker in LBO and M&A with 7 years of previous experience in New York City. He closed dozens of transactions worth a total of $5.0+ billion in secured financing, with a focus on Healthcare and Consumer deals. He is fluent in English and French with international experience gained in NYC, Boston, Paris and Melbourne. He has been living in New York City since 2011.   Contact Information Nicolas Nemeth  Karl Buhler  Additional Resources Dumbo Health Bonne et Filou Thank you for listening! Don't forget to SUBSCRIBE to the show to receive every new episode delivered straight to your podcast player every week. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Deezer, Amazon Music or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

How AI Aligned Marketing and Sales in Seven Months If you have ever felt like your marketing and sales teams are speaking two different languages, or that your best customer stories are locked away in someone's inbox instead of helping close deals, this episode is for you. Host Adam Turinas sat down with Jennifer Lazarz, Director of Marketing at Medical Informatics Corp, the company behind the SickBay Clinical Platform. In just seven months, Jennifer's team went from siloed content and frustrated salespeople to a three-pronged AI infrastructure that has fundamentally changed how marketing and sales work together. We get into the details of how she trained her team on generative AI tools, how she built consolidated document libraries in NotebookLM so salespeople stop chasing down information, and how she put FDA compliance guardrails in place so that everything the AI generates stays within the lines. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Have you ever wondered what truly drives someone to leap from curiosity about startups into the realm of angel investing—and what mindset shifts are crucial along the way? This episode of The Angel Next Door Podcast opens with that very question, as we explore the often untold personal and financial journeys that lie behind the checks investors write, and the ambitions founders chase. Our guest, Christa Downey, brings a unique lens as both an active angel investor and a leadership coach grounded in the vibrant startup ecosystem of Ithaca, New York. Christa Downey shares her path from engaging with the Cornell entrepreneurship community to backing mission-driven companies, investing alongside platforms like Chloe Capital and The Fourth Effect, and leveraging alternative vehicles such as self-directed IRAs to build wealth with purpose. Her commitment to fostering both financial returns and meaningful impact defines her approach and investments. In this conversation, Christa Downey dives into practical strategies for diversification, the pivotal role of money mindset for both founders and investors, and the often-overlooked emotional aspects of entrepreneurship—including navigating hard money conversations, founder agreements, and the difficult transition from founder to CEO. Listeners will gain concrete insights on angel investing, alternative wealth-building tools, and how intentional financial choices shape both companies and their leaders. This episode is a must-listen for anyone interested in reimagining their relationship with money, understanding the nuts and bolts of early-stage investing, and supporting the creation of a more inclusive, impactful startup culture.   To get the latest from Christa Downey, you can follow her below! https://www.linkedin.com/in/christabdowney/   Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing! Website: www.marciadawood.com Learn more about the documentary Show Her the Money: www.showherthemoneymovie.com And don't forget to follow us wherever you are! Apple Podcasts: https://pod.link/1586445642.apple Spotify: https://pod.link/1586445642.spotify LinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/ Instagram: https://www.instagram.com/theangelnextdoorpodcast/ TikTok: https://www.tiktok.com/@marciadawood

This week on Pulse: Amplify, Louise and George sit down with Professor Enrico Coiera - founder of the Australian Alliance for AI in Healthcare and lead author of Don't Walk. Run., the third National Policy Roadmap for AI in Healthcare. Enrico walks us through the Roadmap's 28 recommendations across eight priority areas, and we put it up against the Albanese government's new Office of AI and the national AI standards due to be legislated in early 2027 - asking whether a whole-of-government framework can do justice to a sector as complex as health. We also get into sovereign capability, the arrival of powerful open-weight models like Kimi K3, and what happens when the hyperscalers become the front door to healthcare.With Thanks to Datacom:Download the Executive Briefing Playbook LinkDownload ‘Don't Walk. Run.' hereConnect with Professor Coiera on LinkedInVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

Healthcare companies are built to improve patients' lives. So why do so many prioritize shareholders over the people they're meant to serve?This week, Halle sits down with Eric Ries, author of Incorruptible, to unpack the rise of shareholder primacy, what it is, and why he believes it's at the root of many of society's biggest challenges. They discuss the surprising history of corporate governance, the lessons behind Novo Nordisk's century-long success, and what founders can do today to keep their companies aligned with their mission as they grow.We cover:Why shareholder primacy reshaped corporate America (and where we go from here)How Novo Nordisk's unusual ownership structure may have saved GLP-1 researchThe simple governance change that could preserve your company's mission for decadesHow boards, investors, and acquisitions can slowly pull companies away from their original purposeThe founder mistakes that make mission drift almost inevitableAbout our guest:Over the last two decades, Eric Ries's ideas about continuous innovation, long-term thinking, governance, and market reform have reshaped company building and management practices. He is the creator of the Lean Startup method, and the author of two New York Times bestsellers The Lean Startup and Incorruptible; The Leader's Guide; and The Startup Way. As a founder, he has put his own ideas into practice with The Long-Term Stock Exchange (LTSE); Answer.AI, an AI R&D lab; Virgil, a legal services startup; and IMVU. On The Eric Ries Show, he talks with world-class technologists, thought leaders, and executives building for the long-term. Check out his book, Incorruptible: Why Good Companies Go Bad…and How Great Companies Stay Great—

The State of Healthtech Marketing – Mid-Year Check-in Over the last month, host Adam Turinas has spoken with more than 30 health tech marketing leaders who are part of the Healthtech Marketing Network. He wanted to hear firsthand from them about how the first half of the year has gone and how they're feeling about the rest of 2026. He was surprised by what I heard. On this episode, he sits down with his colleague Mark Erwich, Chief Strategy Officer at Health Launchpad, to discuss what they learned. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode of Medsider Radio, we sat down with Bob Paulson, President and CEO of Sonex Health. Sonex's UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Bob Paulson, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:19) - Bob's path from Medtronic to multiple medtech exits before joining Sonex (05:38) - Why 80% of eligible carpal tunnel patients avoid surgery — and how Sonex is changing that (11:11) - The reimbursement challenge that reshaped Sonex's clinical evidence strategy (19:07) - Reimbursement is a three-leg process: FDA, CPT, and payer coverage (22:07) - Reverse engineering your company from the exit you're trying to achieve (29:35) - How Sonex helped surgeons move carpal tunnel procedures out of the OR (39:06) - Sonex's "pitcher-catcher" approach to physician and patient adoption (41:59) - Bob's framework for choosing investors who can finance the entire journey, not just the next round

This week on Pulse: Hot Topics, Louise and George look at what happens when digital health stops being a pilot and starts being a system decision — and why, again and again, the technology isn't the hard part.Portugal Buys AI Physiotherapy for an Entire Country — Portugal's National Health Service has contracted Sword Health to make AI-supported physiotherapy available to all 10 million citizens, free after a prescription, prompting the question: are governments shifting from buying AI software to buying AI-delivered healthcare?AI and Accountability: The First Complaints Land — The UK's first complaints about clinicians' inappropriate use of AI have reached professional regulators, arriving well before the evidence base and accountability frameworks are ready.95% of Health Apps Have No Verifiable Regulatory Approval — Rudolf Wagner's analysis found that of nearly 96,000 apps qualifying as Software as a Medical Device, 95% had no verifiable CE marking or FDA authorisation, leaving consumers with no easy way to know what they're actually using.Doctors Want Wearable Data, But Can't Use It — A new AMA(US) survey found 97% of physicians would review data from a patient's wearable, but no more than 6% have actually integrated it, blocked by missing standards, workflow fit, reimbursement and liability.Virtual Care Could Transform Residential Aged Care — Australian researchers found virtual care between aged care homes and GPs improves access and reduces unnecessary hospital visits, but is undermined by poor integration, unreliable networks and limited staff training — the technology works, the system around it doesn't.With Thanks to Datacom:Download the Executive Briefing Playbook LinkResources:Sword Health partners with Portugal's National Health Service LinkFirst complaints made over clinician use of AI, HSJ via Patient Safety Learning Hub LinkEnsuring the clinical impact of medical artificial intelligence, Andreoletti et al., Lancet Digital HealthLinkAnalysis of Software as a Medical Device (SaMD) Compliance in App Store Applications, Rudolf Wagner LinkDocs unable to harness wearables data, survey finds, Axios LinkVirtual care could benefit residential homes – study, Pulse+IT LinkVirtual care in residential aged care homes, Journal of Medical Internet ResearchLinkRecommendations:Clinicians – be part of the research into clinician use of AI, open globally LinkStandards Australia telehealth and virtual care standard LinkThere's An AI For That (TAAFT) newsletter LinkAge-Friendly Futures newsletter, George Gouzounis Link"Welcome to the Land of the Free" — World Cup song by Jason Stills LinkVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

Episode 80 - Tom Whicher is CEO and Co-founder of DrDoctor. He co-founded the company after seeing patients struggle with hospital appointments and has since expanded it across NHS trusts, improving care and patient engagement.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

Over the last decade, the number of drug candidates entering development has doubled, yet the number of successful drug approvals remains flat at ~50 per year.This week, we sit down with Formation Bio founder and CEO Ben Liu. His company has raised more than $600 million to build what he hopes will become the first new enduring pharmaceutical company in decades, powered by AI. Ben explains why he believes clinical development, not drug discovery, is becoming the industry's biggest bottleneck, and how AI could fundamentally change the economics of bringing new medicines to patients.We cover:Why there hasn't there been a big pharma company created since the 1980sWhich drug categories Ben believes could become the next GLP-1s and reshape healthcareWhy Formation Bio chose to become a pharmaceutical company instead of selling softwareThe real bottleneck in bringing medicines to patientsBen's roadmap for how AI will transform drug development over the next 10 to 20 yearsAbout our guest:Ben Liu is the co-founder and CEO of Formation Bio. He received his DPhil at Oxford as a Rhodes Scholar, leveraging machine-learning, AI, and big-data to develop diagnostics and therapeutics for Parkinson's and Alzheimer's disease. During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start Formation Bio.Before Formation Bio, Ben graduated from Yale where he was awarded the college's highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Mellon Fellow. Ben also serves as an Advisor to Harvard Business School's MS/MBA Program in Biotechnology.—

How Peer-Reviewed Evidence Drives AI Discoverability If a potential buyer asked an AI chatbot which companies are leading in your space, would your company come up? And if it did, would the answer be positive? On this episode, host Adam Turinas sits down with Paul Wicks, Founder and Chief Evidence Officer of ProofStack Health, and colleague Mark Erwich, Chief Strategy Officer of Health Launchpad, to dig into an underappreciated aspect of B2B health tech: the power of hard evidence.

Join host Eve Cunningham, MD, Chief Medical Officer at Cadence, in conversation with Dr. Stephanie Lahr, founder of Vital Thread Advisory and one of the earliest physician CIOs in the country. Stephanie's career has been anything but traditional – from internal medicine hospitalist to CMIO to CIO at Monument Health, then President of Artisight, and now running her own fractional executive advisory practice. In this episode, Drs. Eve and Stephanie trace that journey and dig into what it really takes for clinicians to make the leap into health tech leadership. Their conversation covers: Why the non-traditional physician career path is rarely planned and why that's okay How clinical skills like systems thinking, change management, and communication translate directly into health tech leadership What it feels like to cross from the provider side to the vendor side, including the isolation nobody talks about Why the health tech industry is hungry for physician experience, and what fractional and advisory work looks like in practice The gap in community and mentorship for physicians navigating non-traditional careers and what needs to come next Segments: Introduction – Eve welcomes Dr. Lahr and frames her non-traditional career arc Origin story – From OB-GYN to internal medicine, and building a hospitalist program in Coeur d'Alene The hand-raise moment – How a question to a CEO about EHR led to an informatics career CMIO to CIO – How Monument Health's CEO saw something different, and how Chime's CIO bootcamp filled the gaps Leading 200 people – What Stephanie misses most about being inside a health system Crossing to the vendor side – The pace, the loneliness, and learning to wear the buyer's lens The Artisight chapter – Smart hospital technology, startup culture, and what the commercial side taught her Speaking it into existence –  Why she's thinking about building a new community for physicians in industry - Vital Thread Advisory — Why fractional work was scarier than any previous pivot, and why it's working Closing advice — Be bold, think outside the box, and never stop learning

They built a $1.2 billion healthcare AI company in under three years, but they say the hardest part of healthcare AI isn't the AI.This week, Halle sits down with Assort Health co-founders and co-CEOs Jeffery Liu and Jon Wang, whose company reached a $1.2 billion valuation in under three years. They discuss why building great healthcare AI takes far more than good models, how they scaled from 15 employees to nearly 250 in a year, and what they've learned from more than 190 million patient interactions. They also share why voice AI is harder than it looks, how they're thinking about building durable moats in the age of foundation models, and why helping patients navigate the healthcare system may be one of AI's biggest opportunities.We cover:The AI role suddenly showing up at every healthcare startupThe surprising demographic that gives AI voice agents the highest satisfaction scoresHow healthcare AI is shifting from single-purpose tools to platforms that remember patients across every interactionWhy the biggest moat in healthcare AI may not be the model itselfThe biggest misconception investors have about moats in healthcare AIHow to triple your team without losing the culture that made the company successful—

In this episode of Medsider Radio, we sat down with Dr. Sudhir Srivastava, founder, chairman, and CEO of SS Innovations (Nasdaq: SSII). The company's SSi Mantra surgical robotic system supports a variety of surgical robotic procedures, including cardiac surgery. Sudhir brings more than three decades of experience in minimally invasive and robotic cardiac interventions, having served as Director of Robotic Cardiac Surgery at the University of Chicago and founder of the International College of Robotic Surgery. A pioneer in the field, Sudhir has performed more than 1,400 robotic procedures, including over 750 beating-heart totally endoscopic coronary artery bypass (TECAB) surgeries.In this interview, Sudhir discusses what it takes to democratize robotic surgery beyond affordability, how SS Innovations built teleproctoring, telesurgery, and the supporting infrastructure for its robotic platform, and his milestone-based approach to financing a capital-intensive medtech company. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Sudhir Srivastava, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:01) - Sudhir's journey from performing the world's first beating-heart robotic bypass to founding SS Innovations (07:14) - The 22-year-old patient who became the catalyst for Sudhir's affordable robotic surgery platform (08:59) - Building Mantra 3 from the ground up in just five months (12:14) - Inside the engineering process that eliminated months of costly iteration (16:20) - The question that shaped SS Innovations: "How do you democratize access?" (27:10) - From one office to performing 24 telesurgeries in 12 hours across India (29:29) - How a mobile training bus became part of Sudhir's answer to make robotic surgery accessible (33:49) - Lessons from commercializing a surgical robotics platform across developing markets (39:43) - Starting with just $5 million: Sudhir's milestone-based approach to fundraising

Over the last month, I have spoken with more than 30 health tech marketing leaders who are part of the Healthtech Marketing Network. I wanted to hear firsthand from them about how the first half of the year has gone and how they're feeling about the rest of 2026.I was surprised by what I heard.In this episode, I sit down with my colleague Mark Erwich, Chief Strategy Officer at Health Launchpad, to discuss what we learned.We get into what happened in the first half of the year versus what people expected, and why almost nobody feels comfortable heading into the second half. One thing that stood out was that success is uneven. Some companies are doing better than others, and we unpack why.We also cover some real shifts in the buying process this year: How the C-Suite is getting more involved, how expectations are changing, and changes in buying committee dynamics.If you want a genuinely candid, no slides, no frameworks read on where healthtech marketing stands right now, this is the episode for you.Key Topics Covered:"(00:00)" – Introduction"(01:00)" – One word to describe H1: change"(03:00)" – Mark's take: positive policy and funding shifts"(05:00)" – Where healthcare tech spending is actually shifting"(06:00)" – Headwinds: Medicaid uncertainty, ROI scrutiny, Epic's expanding footprint"(09:00)" – The bifurcating "(or trifurcating)" market"(12:00)" – Three shifts in the buying process"(14:00)" – The dynamic buying committee concept and champion enablement"(17:30)" – AI maturity self-assessment: most teams landing at four to five out of ten"(18:00)" – AI-driven lead scoring"(19:00)" – Mark's perspective on tracking 100+ AI marketing use cases"(21:00)" – The AI volume paradox: more efficient tools, harder workloads"(22:00)" – Health Launchpad's GTM strategy offer for H2 planning"(23:00)" – The direct mail renaissance"(25:00)" – Brand awareness at scale"(27:00)" – Turning happy clients into brand ambassadors"(28:00)" – LLM optimization and the debate over signal capture versus unique content"(32:00)" – Reflections on differentiation across competitors this year"(33:00)" – Mark's closing advice: pick one thing and do it well"(34:00)" – Adam's five takeaways and episode wrap-upIf you are interested in discussing this or any other topic, let's have a chat.  Reach out to me directly to schedule a no-obligation discussion. This isn't a sales call, but rather an opportunity to talk through your questions and challenges.Follow me on LinkedIn.Subscribe to The Healthtech Marketing Show on Spotify or watch us on YouTube for more insights into marketing, AI, ABM, buyer journeys, and beyond!Thank you to our presenting sponsor, HealthcareNOW, 24/7 expert shows, interviews, and podcasts, powering healthcare leaders with innovation, policy, and strategy insights.

How to Build Pipeline With Podcasts One of the questions host Adam Turinas often hear most from healthtech marketers is whether starting a podcast is actually worth it. And if you already have one, are you thinking about it the right way? He brought on two guests who have built one of the most distinctive shows in healthtech together: Ed Gaudet, CEO and Founder of Censinet, and his brother Mark Gaudet, Director of Market Development at Censinet and the host of their podcast, Risk Never Sleeps, which just hit 200 episodes. This conversation gets past the usual “build your brand” rationale for podcasting and into the real, honest story of what it actually takes and what it actually delivers. Ed and Mark talk about the grind of those first six months, why most podcasts never make it past 25 episodes, and how Risk Never Sleeps has become a genuine source of pipeline for Censinet. Adam share his own experience too, including how syndication 5X'd our reach and how listeners have turned into real business conversations. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Episode 79 - Julian co-founded Asterix Health in 2024 after his own experience with heart valve disease. At Asterix, he's tackling the shortage of qualified clinical staff with a model that's already supporting 250K patients across the UK.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

July marks five years of The Heart of Healthcare, and we're grateful for every listener who's tuned in. If you've enjoyed the show, please show your love by leaving us a review!This month, Steve and Halle take stock of an industry where capital is concentrating, incumbents are making big bets, AI is moving from promise to early proof points, and a public health crisis is quietly building in the background.We cover:The digital health funding numbers that just dropped, and what they reveal about where the money is really goingA $12 billion deal that has the RCM world buzzingThe Nature study that has clinical AI companies on edgeA new entrant into medical imaging that nobody saw comingThe public health crisis that sports betting built, and why healthcare isn't talking about it enoughEarly data out of Utah that could change how we think about AI in clinical settingsLinks:IPO Watch List: https://halletecco.substack.com/p/the-digital-health-ipo-watchlistEnsemble Health / Thoreau deal: https://hitconsultant.net/2026/06/18/thoreau-makes-strategic-investment-in-ensemble-health/Nature Medicine AI study: https://www.nature.com/articles/s41591-026-04431-5Midjourney Medical: https://www.theverge.com/ai-artificial-intelligence/952011/midjourney-medical-ai-ultrasound-scanDoctronic pilot outcomes: https://commerce.utah.gov/wp-content/uploads/2026/05/Doctronic-Outcomes-May-2026.pdf—

In this episode of Medsider Radio, we sat down with Aditya Rajagopal, co-founder and CEO of Esperto Medical.Esperto is a Caltech spin-out utilizing compressed sensing technology with ultrasound to continuously and non-invasively measure blood pressure.Before Esperto, Aditya co-founded ChromaCode, a molecular diagnostics company, and was a researcher at Google[x], where he worked on novel medical imaging methods. Aditya also serves as part-time faculty at Caltech and USC, and holds BS, MS, and PhD degrees in Electrical Engineering from Caltech. In this interview, Aditya discusses why great science doesn't necessarily make great companies, what it takes to win as a fast-follower in medtech, and how to sequence a platform technology without spreading resources too thin.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Aditya Rajagopal, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(02:44) - Aditya's journey from Caltech and Google to tackling one of medicine's hardest engineering problems at Esperto (05:17) - How Esperto is trying to solve a 50-year-old problem: continuous blood pressure monitoring without an arterial catheter (07:17) - Why Esperto was okay with being a fast-follower in an established market instead of creating a new one (16:12) - "Great science doesn't necessarily make great companies" and other lessons Aditya learned at ChromaCode (24:02) - Three hurdles every medical device must clear before clinicians will actually adopt it (27:44) - How Aditya determines whether a technical problem actually has a "there there" (37:51) - Esperto's pitch strategy and how it raised from a position of strength (43:18) - What first-time founders often misunderstand about how venture capital actually works

The Low Volume, High Intent Era: What AI Search Is Doing to Health Tech Buyer Behavior Something fundamental has changed in how health tech buyers do research, and if you're watching your website traffic decline, you might be misreading what it actually means. On this episode host Adam Turinas sits down with Suyog Deshpande, Founder and CEO of Webless AI, to dig into one of the most consequential shifts in B2B buyer behavior in a generation. Here's what's actually happening: your buyers haven't stopped doing research. They've moved it upstream — to ChatGPT, Claude, Perplexity, and Gemini. They're building their shortlists there, forming their preferences there, all before they ever land on your website. By the time they show up, they're not browsing. They're validating. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Back by popular demand, 3x Heart of Healthcare guest Eric Larsen joins Steve to answer listener questions on healthcare's AI revolution. Drawing on the ideas behind his latest essay, Healthcare's Oppenheimer Moment, Eric argues that healthcare may be approaching a once-in-a-generation inflection point, and discusses what leaders need to understand before it's too late.We cover:Whether foundation models will eventually outperform healthcare-specific AI companiesWhy healthcare remains stuck in AI pilot projects while the technology races aheadThe biggest obstacle to clinical AI adoptionWhy liability may be the most important (and least discussed) issue in healthcare AIEric's controversial take on how AI will reshape the healthcare workforce—Links:Eric's essay is available here —

Why Medtech Commercial Strategies Stall and How to Fix Them One of the most common and costly mistakes in medtech commercialization is confusing clinical buy-in with commercial buy-in. A surgeon who loves your device, peer-reviewed data supporting it, and a field rep with a 20-year relationship can all be in place, and the deal can still stall out completely. Why? Because the doctor is not the buyer. On this episode host Adam Turinas sits down with Todd Laderach, a medtech commercial strategy veteran with over two decades of experience across sales, marketing, and go-to-market leadership. Todd now runs his own firm helping device companies get life-saving products off the shelf and into the hands of clinicians, and he brings a clarity to the commercial realities of medical device selling that I think will resonate well beyond the device world. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Most people are already asking AI about their health. Almost none of them believe the answers. Around 40% use it to make wellness choices, but fewer than 5% trust what it says. Matt Watson and Josh Anthony, CEO of Nlumn, dig into why.Josh has spent 25 years in food and nutrition, and his take is blunt: trust drops fast as the question gets serious, from a recipe to a diagnosis, and the fix isn't a smarter chatbot. It's pairing the data with a human people actually trust. They cover what's real right now too. The protein obsession. Beans having a moment. GLP-1s and why weight loss is now about saving muscle, not just dropping fat. Why people are building their own messy personalization stacks because no single company does it well.Matt also explains why he flat out ignores his doctors on cholesterol, and he and Josh go a few rounds on whether ultra-processed food is the problem or a missed opportunity.If you build or invest in health products, listen now. And if you want help with personalized nutrition, reach Josh@nlumn.com or info@nlumn.com.⏱️ Episode Breakdown00:28 Introduction to Health Tech and AI03:36 Trust in AI for Health and Nutrition06:29 Personalization in Health and Nutrition09:26 Emerging Trends in Health Tech12:23 The Role of GLP-1 in Weight Management15:29 Challenges in the Food Industry18:37 Innovative Products in Health and NutritionLinks & ResourcesConnect with Joshua Anthony on LinkedInNlumn Website - https://www.nlumn.com/Email - mailto: info@nlumn.comWhat Smart CTOs Are Doing Differently With Offshore Teams in 2025Subscribe to the Global Talent SprintFull Scale – Build your dev team quickly and affordablyIf you're trying to get your team out of the basement and into real product ownership, this episode is your playbook. Stop being a ticket factory. Build teams that think, create, and lead.

Dr. Jason Wersland turned a 3 a.m. garage experiment into the number one percussive therapy brand in the world, with more than 6.5 million Theragun massage devices sold. In this episode, he breaks down the unglamorous eight-year grind behind that overnight success: five prototypes, three bad partners, and a one-to-one credibility-building strategy that eventually landed him in Cristiano Ronaldo''s training room. For more on Therabody and show notes click here   Subscribe and watch Shopify Masters on YouTube!Sign up for your FREE Shopify Trial here.

Healthcare AI funding is booming, but the money is flowing to fewer companies than ever before. As investors pour capital into a small group of breakout winners, founders are navigating a fundraising environment where expectations seem to change every quarter. Based on interviews with 24 healthcare founders and a dozen healthcare investors, Halle breaks down what is actually happening in the market today, from pitch meetings and diligence processes to the growing debate over whether AI has fundamentally changed venture capital itself. Why healthcare AI fundraising has become a tale of two marketsThe two questions dominating investor meetings in 2026The metrics VCs are looking for todayThe debate over whether investors should abandon traditional ownership targetsWhy high valuations can be both a gift and a trap for founders —Show notes:Submit questions for our Eric Larsen healthcare AI Q&A here Part I: AI ate digital health (and what that means for fundraising)Part II: Convicted or disciplined: How healthcare VCs are split on investing—

In this episode, I'm joined by Max, co-founder of Superpower, a longevity and preventive health company based in San Francisco. Max shares his unconventional journey from a curious, entrepreneurial kid in Sydney to building one of health tech's most ambitious startups — all without a clinical background. He offers a refreshingly direct perspective on why clinicians are uniquely positioned to drive change in healthcare, why sunk cost is a trap, and why the best time to make your move is now. If you're a healthcare professional thinking about stepping into health tech, this episode will challenge the way you think about your career.Quotes:"Health professionals are some of the best placed to actually create change in health." - Max"Servicing a system allows you to impact maybe a few hundred or thousand people. Building a system ideally gets to the millions over time." - Max"The fastest path between A and Z is not to go through B, C, D — just do the thing." - Max"Being willing to be dumb is almost a prerequisite to being smart." - Max"If you're trying to do something in a new way, it's very hard to do that from the model of thinking that created the existing way." - MaxShow Notes:Why clinicians have an unfair advantage when building in health techHow to stop letting sunk cost hold you back from a career pivotThe difference between servicing the healthcare system and building itWhy the "one day I'll do this" mindset is keeping you stuckHow an outsider perspective can be the most powerful tool for reinventing healthcareLinks: https://www.matchday.health/ https://superpower.com/ https://www.linkedin.com/in/maxmarchione/